Cargando…
New drug approvals in acute myeloid leukemia: what’s the best end point?
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777773/ https://www.ncbi.nlm.nih.gov/pubmed/26677969 http://dx.doi.org/10.1038/leu.2015.262 |
| _version_ | 1782419352175247360 |
|---|---|
| author | Estey, E Othus, M Lee, S J Appelbaum, F R Gale, R P |
| author_facet | Estey, E Othus, M Lee, S J Appelbaum, F R Gale, R P |
| author_sort | Estey, E |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4777773 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-47777732016-03-14 New drug approvals in acute myeloid leukemia: what’s the best end point? Estey, E Othus, M Lee, S J Appelbaum, F R Gale, R P Leukemia Article Nature Publishing Group UK 2015-12-18 2016 /pmc/articles/PMC4777773/ /pubmed/26677969 http://dx.doi.org/10.1038/leu.2015.262 Text en © The Author(s) 2016 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| spellingShingle | Article Estey, E Othus, M Lee, S J Appelbaum, F R Gale, R P New drug approvals in acute myeloid leukemia: what’s the best end point? |
| title | New drug approvals in acute myeloid leukemia: what’s the best end point? |
| title_full | New drug approvals in acute myeloid leukemia: what’s the best end point? |
| title_fullStr | New drug approvals in acute myeloid leukemia: what’s the best end point? |
| title_full_unstemmed | New drug approvals in acute myeloid leukemia: what’s the best end point? |
| title_short | New drug approvals in acute myeloid leukemia: what’s the best end point? |
| title_sort | new drug approvals in acute myeloid leukemia: what’s the best end point? |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777773/ https://www.ncbi.nlm.nih.gov/pubmed/26677969 http://dx.doi.org/10.1038/leu.2015.262 |
| work_keys_str_mv | AT esteye newdrugapprovalsinacutemyeloidleukemiawhatsthebestendpoint AT othusm newdrugapprovalsinacutemyeloidleukemiawhatsthebestendpoint AT leesj newdrugapprovalsinacutemyeloidleukemiawhatsthebestendpoint AT appelbaumfr newdrugapprovalsinacutemyeloidleukemiawhatsthebestendpoint AT galerp newdrugapprovalsinacutemyeloidleukemiawhatsthebestendpoint |